Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves First Anti-PDL1 Cancer Immunotherapy for Metastatic Lung Cancer

XTALKS VITALS NEWS

Lung Cancer

The anti-PDL1 cancer immunotherapy is indicated for patients with tumors containing EGFR or ALK gene abnormities, and those who have experienced disease progression following platinum-containing chemotherapy.

Tweetables from this article:

Tweet: Patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel #chemotherapy http://ctt.ec/_Xe84+ Patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel chemotherapy.

Share this!

October 20, 2016 | by Sarah Hand, M.Sc.

Roche’s biotechnology division, Genentech, has just received US Food and Drug Administration (FDA) approval for their non-small cell lung cancer drug, Tecentriq (atezolizumab). The anti-PDL1 cancer immunotherapy is indicated for patients with tumors containing EGFR or ALK gene abnormities, and those who have experienced disease progression following platinum-containing chemotherapy.

The FDA approval was based on data collected during a Phase II clinical trial – dubbed POPLAR – along with a Phase II study, known as OAK. In the OAK clinical trial, patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel chemotherapy.

“Tecentriq is a new option to help people with this type of previously treated metastatic lung cancer, regardless of PD-L1 expression, live longer than chemotherapy,” said Dr. Sandra Horning, chief medical officer and head of global product development for Genentech. “Tecentriq is the first and only approved cancer immunotherapy designed to target the PD-L1 protein, which may play an important role in the way the medicine works.”



The OAK clinical trial enrolled patients with both squamous and non-squamous types of lung cancer, and did not discriminate based on PD-L1 status. In all, over 15 clinical trials have been conducted to assess Tecentriq, including seven Phase III studies using the immunotherapy as a possible first-line treatment for lung cancer.

Tecentriq is a monoclonal antibody which binds to the PD-L1 protein expressed on certain tumor cells. As an immunotherapy, the drug is designed to stimulate the activation of T cells to detect and destroy cancer cells. The Phase III OAK clinical trial is a global, multicenter, open-label, randomized, controlled study, which compared the safety and efficacy of Tecentriq compared to docetaxel, in 1,225 patients with NSCLC.

“Over the past 15 years, survival rates for advanced lung cancer have been consistently improving,” said Bonnie J. Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (ALCF). “The approval of Tecentriq is another important step for patients by increasing the number of medicines available to people living with lung cancer.”

Over 224,000 Americans will be diagnosed with lung cancer this year, according to statistics from the American Cancer Society. NSCLC accounts for almost 85 percent of lung cancer cases, with many diagnoses being made once the disease has entered the most advanced stages.


Keywords: Lung Cancer, Immunotherapy, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.